07 August 2002
Meta-analysis of 20 case-control studies on the N-acetyltransferase 2 acetylation status and colorectal cancer risk
Zheng Ye, James M. ParryMed Sci Monit 2002; 8(8): CR558-565 :: ID: 13598
Abstract
Background: Rapid NAT2 acetylation has been considered as a risk factor for developing colon cancer in a number of studies, however the overall results of such studies are inconsistent. To clarify the
influence of NAT2 rapid acetylation status on colon cancer risk, we have performed a metaanalysis of 20 published case-control studies (4431 cases, 4547 controls).
Material/Methods: Odd ratio was employed to evaluate the risk of colon cancer and NAT2 rapid acetylation status. To take into account the possibility of heterogeneity across the studies, a statistical test for
heterogeneity across the studies was performed. The summary odds ratios were assessed by calculating a weighted average of odds ratios for all of the studies.
Results: The pooling of studies based on phenotyping methods indicated that the overall odds ratio of colon cancer risk associated with rapid acetylator was 1.51 (95%CI: 1.07–2.12). However, the
risk of colon cancer associated with rapid acetylator from the studies based on genotyping method was lower with a calculated overall odds ratio of 1.06 (95%CI: 0.97–1.15). Pooling studies were also conducted on specific tumour sites and ethnic groups. The results show that
effect of rapid acetylator on colon cancer risk was not obviously different.
Conclusions: The results of our meta-analyses do not support the hypothesis that NAT2 alone is an important risk factor for colon cancer and suggests that NAT2 rapid acetylation status has no specific
effect on the risk of developing colon cancer
Keywords: Acetylation, Arylamine N-Acetyltransferase - metabolism, Case-Control Studies, Colorectal Neoplasms - enzymology, Colorectal Neoplasms - etiology, Odds Ratio, Risk Factors
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
11 Mar 2024 : Clinical Research
Enhancement of Frozen-Thawed Human Sperm Quality with Zinc as a Cryoprotective AdditiveMed Sci Monit In Press; DOI: 10.12659/MSM.942946
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952